EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 182 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Tepotinib December 23, 2021 Cancer “Liquid Biopsy” Blood Test Gets Expanded FDA Approval November 30, 2020 EMA Recommends Extending Indications for Pembrolizumab to Include Adjuvant Treatment in... October 6, 2023 Screening for Many Cancers with One Test: Uncertainty Abounds April 21, 2022 Load more HOT NEWS Imaging Test Could Help Guide Breast Cancer Treatment Decisions Adding Capivasertib to Fulvestrant Results in Longer PFS in Patients with... FDA Approves Selinexor for Relapsed/Refractory Diffuse Large B-Cell Lymphoma FDA Grants Regular Approval to Sacituzumab Govitecan for Advanced Triple-Negative Breast...
